ELYM vs. RAPT, INZY, XOMA, XBIT, XERS, CTMX, ENTA, VSTM, NKTR, and AKBA
Should you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include RAPT Therapeutics (RAPT), Inozyme Pharma (INZY), XOMA (XOMA), XBiotech (XBIT), Xeris Biopharma (XERS), CytomX Therapeutics (CTMX), Enanta Pharmaceuticals (ENTA), Verastem (VSTM), Nektar Therapeutics (NKTR), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.
RAPT Therapeutics (NASDAQ:RAPT) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
99.1% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by insiders. Comparatively, 3.2% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Eliem Therapeutics has lower revenue, but higher earnings than RAPT Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, RAPT Therapeutics had 15 more articles in the media than Eliem Therapeutics. MarketBeat recorded 18 mentions for RAPT Therapeutics and 3 mentions for Eliem Therapeutics. RAPT Therapeutics' average media sentiment score of 1.60 beat Eliem Therapeutics' score of -0.29 indicating that Eliem Therapeutics is being referred to more favorably in the news media.
RAPT Therapeutics received 79 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave RAPT Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
RAPT Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500.
RAPT Therapeutics currently has a consensus price target of $24.67, suggesting a potential upside of 460.61%. Given Eliem Therapeutics' higher probable upside, equities analysts plainly believe RAPT Therapeutics is more favorable than Eliem Therapeutics.
RAPT Therapeutics' return on equity of -31.45% beat Eliem Therapeutics' return on equity.
Summary
RAPT Therapeutics beats Eliem Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Eliem Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eliem Therapeutics Competitors List
Related Companies and Tools
